hims glp-1 pills cancels plans to sell compounded pill after FDA backlash Hims introduces GLP-1 weight loss

*The anti-obesity drugs' estimated percentile ranking of weight loss of 10% in participants who took weight-loss medications for more than a year is Phentermine-Topiramate, 54%

Obesity is associated with many life-threatening diseases, including (but not limited to) diabetes, cancer, hormonal issues, stroke and cardiovascular disease

The potential delay factor is the triple-agonist novelty

Most diminish after 2 to 4 weeks at each dose level as your body adjusts

Trial status (May 2026): Eli Lilly reported positive topline results from the Phase 3 TRIUMPH-1 obesity trial on May 21, 2026, with mean weight reduction of 28.3% at 80 weeks on the 12 mg arm [1][2]

Also, the industry is influenced by more convenient treatment pathways, including oral GLP-1 therapies and digitally enabled prescription access